Cytosurge

Executive Summary

Cytosurge AG, based in Glattbrugg, Switzerland, is pioneering single-cell manipulation through its patented FluidFM technology. Founded in 2012, the company’s platform enables precise microinjection and extraction of substances into individual cells while maintaining high viability—a critical capability for emerging cell therapy and drug delivery applications. By combining atomic force microscopy with microfluidics, FluidFM offers researchers and biomanufacturers an unparalleled tool for genetic engineering, cell line development, and therapeutic payload delivery. With broad applicability across cell types, the technology addresses key bottlenecks in cell therapy manufacturing, such as consistent genetic modification and targeted drug delivery, positioning Cytosurge as a key enabler in the precision medicine revolution. Cytosurge operates in the rapidly growing cell therapy and drug delivery markets, projected to reach tens of billions in value over the next decade. Despite being a private, pre-revenue company with no disclosed funding rounds, its technology has attracted attention from academic and industry partners. The company’s focus on automation and scalability suggests potential for commercial adoption in both research and clinical applications. However, execution risks remain, including competition from other single-cell manipulation techniques and the need for robust manufacturing partnerships. If successful, Cytosurge could become a standard tool in cell engineering workflows.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major Pharma for Cell Therapy Applications60% success
• Q4 2026Launch of Next-Generation Automated FluidFM System70% success
• Q2 2026FDA Breakthrough Device Designation for Drug Delivery Platform50% success